EUA Template for At-Home COVID-19 Sample Collection Kits

by | Jun 12, 2020 | Coronavirus, COVID-19, FDA, Medical Devices, Requirements

The FDA has recently released a new emergency use authorization (EUA) template aimed at developers of at-home sample collection kits for COVID-19 tests. EUA’s are the FDA’s provision which allows the use of unapproved medical products when there are no other adequate or available alternatives. This newly released template lays out the FDA’s current thinking on what data and information developers should submit in order to facilitate and streamline the EUA process.

The template is aimed at home sample collection for molecular diagnostic testing which is developed by either laboratories or commercial manufacturers. Additionally, this template only applies to prescription use home collection devices that utilize anterior nasal swab or saliva specimens. Any developers who are considering other types of specimens (i.e. tongue swabs or stool samples) are instructed to contact the FDA directly to discuss validation strategy.1

The template information itself walks the developer through all the information necessary to submit the EUA. It covers administrative information such as purpose for submission, applicant information, and even has a pre-filled approval/clearance status disclaimer. The template then moves into the proposed intended use section, which is partially completed and has easy-to-understand fillable sections. The information the developer is responsible for completing includes what type of specimen the device collects, the mechanism via which the individual is determined to be appropriate for COVID-19 testing, and the name of the laboratories that will be testing the samples. Other sections of the template walk developers through:

  • Device Description (including specimen collection control and processing)
  • Product Manufacturing
  • Performance Evaluation
  • Instructions for Use
  • Record Keeping and Reporting Information to the FDA2

The FDA has been developing EUA templates as part of an interactive review for Pre-EUA/EUA submissions and will likely continue to update them to facilitate the application process for developers. If you are developing a home sample collection kit for COVID-19 and need help applying for an EUA, EMMA International has the expertise to help! Give us a call at 248-987-4497 or email to get started.

1FDA (May 2020) FDA takes steps to streamline development of tests with at-home sample collection retrieved on 06/10/2020 from:

2FDA (May 2020) Policy for Coronavirus Disease-2019 Tests during the Public Health Emergency (Revised) retrieved on 06/10/2020 from:

Madison Wheeler

Madison Wheeler

Director of Technical Operations - Ms. Wheeler serves as EMMA International’s Director of Technical Operations. She has experience in technical writing, nonconforming product management, issue evaluations, and implementing corrective and preventative actions in the pharmaceuticals and medical device industries. She has experience cross-functionally between R&D, lean manufacturing operations, and RA compliance. Ms. Wheeler also has academic and work experience with human health-risk engineering controls, physiological biophysics, and clinical research. Ms. Wheeler holds a Bachelor of Science in Biosystems Engineering with a concentration in Biomedical Engineering from Michigan State University. She is also a Certified Quality Auditor (CQA), and is currently pursuing her M.S. in Quality Management.

More Resources

FDA’s Refusal to Accept Process

FDA’s Refusal to Accept Process

Before the submission of a 510(k) premarket notification, the purpose of which is to notify the FDA of the manufacturer’s intent to market a medical device,[i] there is a provision for acceptance review. This review serves as a method to assess whether a submission is administratively complete and includes all necessary information for FDA to determine substantial equivalence under section 513(i) of the Federal Food, Drug, and Cosmetic (FD&C) Act (21 United States Code (U.S.C.) § 360c(i)). To establish substantial equivalence under this provision, FDA must find the same intended use as the predicate device and either have the same technological characteristics as the predicate device or appropriate clinical and scientific data necessary to establish that the device is safe and effective as the predicate device. If the Authority is unable to determine substantial equivalence due to insufficient information, it may request for additional information to make that determination. Therefore, as a part of the acceptance review, the FDA staff follows the acceptance checklist[ii] to ensure that the application is administratively complete. These administrative elements are identified as RTA items and are required to be presented. The purpose of conducting the acceptance review is for the Lead Reviewer to determine whether the 510(k) submission meets the minimum threshold of acceptability and should be accepted for substantive review.[iii]
Empowering Your Workforce through Kaizen

Empowering Your Workforce through Kaizen

Last week, I touched on the idea of involving and empowering all employees in the workplace through the corrective and preventive actions process by fostering taking initiative and a problem-solving (refer to blogpost ‘The Art of Addressing Non-Conformances in Operations’). To expand on this concept a bit further, we’re going to be looking at Kaizen–a continuous improvement strategy in which employees at all levels are also empowered to solve problems towards big gains.
FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

The pandemic has been a challenging time for all industries including the Food and Drug Administration (FDA). The FDA had to alter the manner in which it conducted its operations. One set of tools adopted by the FDA in response to COVID-19 was the remote regulatory assessment (RRAs).

Ready to learn more about working with us?

Pin It on Pinterest

Share This